HAE Day:-) takes place on 16 May 2013 and aims to raise awareness of Hereditary Angioedema (HAEViroPharma Incorporated, announced its support of the second annual international Hereditary Angioedema DayHAE Day:-) is coordinated by the HAEi, the International Patient Organization for C1 Inhibitor

read more>>

Bayer HealthCare announced that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga® (regorafenib) tablets for the treatment of patients with Stivarga h

read more>>

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced that it has initiated the first clinical study for development of SGX203 (oral beclomethasone

read more>>

Roche announced that important new data from clinical trials of several investigational and approved cancer medicines will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 to June 4, 2013, in Chicago. At the meeting, Roche medicines will be • Ne

read more>>

  Genentech, a member of the Roche Group and Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Tarceva® (erlotinib) tablets for the initial (first-line) treatment of people with metastatic

read more>>

Inovio Pharmaceuticals, Inc. announced that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against

read more>>

Callidus Biopharma, Inc., a development-stage biotechnology company focused on creating breakthrough biologic drugs for a range of orphan diseases, announced that it has closed on $4.6 million in Series A financing led by two strategic investors. The Company intends to use the proceeds to Dr. Hung

read more>>

Even as Jill Wood breathes a little easier knowing several drug discovery programs to treat her son’s rare disease, Sanfilippo syndrome type C, are under way, she’s also aware that the hardest part is yet to come. Testing a drug in kids for rare diseases and gathering enough evidence to convinc

read more>>

Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A. ELOCTATE is the first hemophilia A product

read more>>

It’s the second round of funding received by the Natick, Mass. developer of cancer- and inflammation-targeting drug candidates. Karyopharm raised the $20 million first tranche of its Series A financing in November of 2010. In addition to CEO and Director Michael Kauffman and Chief Scientific Fou

read more>>